Patients with advanced breast cancer that has spread
to other parts or cancer that has recurred often do not respond to chemotherapy
and hardly have any treatment options left.
However, a new drug Eribulin could provide hope in these patients. A study evaluating the effect of Eribulin on
survival in advanced breast cancer was recently published in the Lancet
journal.
Eribulin was tested in a number of women with
metastatic breast cancer (breast cancer that had spread to other organs of the
body) or locally recurrent cancer and who had received heavy chemotherapy
before. Its effect was compared with
other drugs used in clinical practice and selected according to the doctors
choice. The study was called EMBRACE
trial.
Treatment with
Eribulin in this trial improved survival of patients by almost two and a half
months. Side effects of the drug were also possible
to treat.
Eribulin acts at a new site on the cancer cells and
inhibits cell division. It has the
advantages that it can be relatively easily administered, has a short infusion
time and the patient need not be pretreated with any drugs to prevent an
allergic reaction. Eribulin caused side
effects like neutropenia (low WBC count), fatigue and peripheral neuropathy
(problem with nerves that could cause symptoms like tingling, numbness and
muscle weakness). Neutropenia was
managed with reduction and/or delay in the dose and administration of
granulocyte colony stimulating factor.
Based on
this study, Eribulin has been approved in the USA for the treatment of
metastatic breast cancer for those patients that have received at least two
chemotherapeutic regimens. These
regimens should include anticancer drugs from the anthracycline and taxane classes.Source-Medindia